Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SaltX Technology Holding AB (publ) Interim report 1 2020

Interim report 1 2020Financial eventsFirst quarter -Net sales totaled to MSEK 0.1 (-1.7) -Operating profit/loss (EBIT) amounted to MSEK -9.2 (-20.1) -Cash flow from operating activities amounted to MSEK -9.1 (-25.1) -Earnings per share before and after dilution were MSEK -0.12 (-0.29)   Significant events  First quarter  -SaltX Chinese partners initiate construction of a pilot plant -Uncertainty about the effect of covid-19   Interim report 1 can be downloaded at http://saltxtechnology.com under the Investor tab .

Clevegen manufacturing agreement

Faron Pharmaceuticals Oy("Faron" or the "Company")  Faron contracts with AGC Biologics in commercial scale Clevegen manufacturing agreement  Company announcement, 05 May 2020 at 9.00 AM (EEST)Inside informationTURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that global contract development and manufacturing organisation AGC Biologics has been selected to be the commercial scale manufacturer of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive

Notice of Ponsse’s Annual General Meeting

Ponsse Plc’s (“Ponsse”) shareholders are hereby invited to attend the Annual General Meeting to be held on Wednesday 27 May 2020, at 10:00 a.m. EET, in the auditorium of the company’s customer service centre at Ponssentie 22, FI-74200 Vieremä, Finland, using exceptional arrangements due to the coronavirus situation. Reception of those registered for the meeting and the distribution of ballots will begin at 9:30 a.m. EET.Ponsse takes the coronavirus situation seriously and has decided to organise the Annual General Meeting in these exceptional circumstances so that the number of participants

Veidekke ASA: To build new residential project in Malmö

Veidekke Entreprenad has been commissioned by Veidekke Eiendom to build the first stage of Atmosfären, a new residential project in Malmö. The contract has a value of SEK 142 million.The new residential area Atmosfären in Limhamns Sjöstad outside Malmö will comprise 90 units of different sizes. Since sales start in June of last year, the project has attracted great interest, and Veidekke Eiendom has now commissioned Veidekke Entreprenad to build the first stage. This stage encompasses 62 residential units and an underground garage which will service both building stages. Construction will

Interim report January - March 2020

Gothenburg, May 5, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2020.Important events during the first quarter · In January, Vicore issued 243,525 shares to the warrant holders in the incentive programme LTIP 2016. · In the beginning of 2020, the phase II study with C21 in patients with systemic sclerosis (SSc) and Raynaud's phenomenon dosed its first patients. · In March, Vicore submitted a Clinical Trial Application (CTA) to the UK regulatory agency MHRA, for a phase II study with C21 in patients with IPF. The study has been re-

Interim report January-March 2020

KICK-OFF FOR A NEW ORGANIZATION  January-March 2020 · Order bookings amounted to SEK 2,975 million (1,177) and the order backlog was SEK 10,576 million (5,973) · Income amounted to SEK 1,814 million (1,480) · The operating loss was SEK 149 million (profit 18), of which non-recurring expenses amounted to SEK 135 million · At the end of the period, available cash and cash equivalents totaled SEK 587 million · Cash flow from operating activities amounted to an outflow of SEK 233 million (262) · Cash flow for the period amounted to an outflow of SEK 50 million, of which

GlobalConnect appoints Henrik Schibler as new Group CFO

Northern Europe’s leading digital infrastructure provider, GlobalConnect appoints Henrik Schibler as its new Group Chief Financial Officer (CFO). He is currently the European Chief Operating Officer at ISS and will assume his new position on August 10, 2020.“I couldn’t be happier welcoming Henrik to our team. He holds many of the crucial qualities I look for in a strategic and business minded CFO. As GlobalConnect/IP-Only continues to grow with customer centric products and services, Henrik’s contributions will play a key role to our success as we continue our expansion across Northern

Vicore Pharma receives regulatory approval to start phase II clinical trial with VP01 (C21) in patients with IPF

Gothenburg, May 5, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the approval by the UK regulatory agency (MHRA[1]) of the clinical trial application (CTA) for a phase II study with its proprietary compound VP01 (C21) in patients with IPF (idiopathic pulmonary fibrosis).Approximately five weeks after submitting the CTA, Vicore Pharma has received approval from the MHRA to start the study. In addition to the MHRA approval, a favourable opinion from the ethics committee is also required

SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression

· The first of two tested doses (50 mg) identified to be safe and well-tolerated. · The blinded review revealed that patients in the study form two groups based on changes in their clinical disease activity index (CDAI). · Based on the safe and well-tolerated first dose (50 mg) the company now initiates the next dose level (100 mg). SynAct Pharma AB ("SynAct") hereby announces that the company, based on a blinded review of data from the company´s ongoing Phase II study entitled ”A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerability,

Interim Report January–March 2020

Quarter January–March 2020 · Net sales increased by 7 percent to SEK 1,658 (1,544) million · EBITA increased by 65 percent to SEK 62 (37) million · Profit after tax increased to SEK 14 (-1) million · Earnings per ordinary share amounted to SEK -0.02 (-0.21) Events after the reporting period · On 16 April, Volati announced preliminary results for Q1 2020 and issued an update on the impact of the Coronavirus. · On 16 April, Volati is postponing the AGM from 6 May to 25 June 2020. COMMENTS FROM THE CEO A strong first quarter Volati delivered a significantly

Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States

GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced approval of a clinical patent for arfolitixorin in the United States. The patent expires in 2038 and is a divisional patent for the master patent granted in the US in May 2019. The now granted patent (US 10,639,311) is more specifically focused on the dose regimen used in the ongoing clinical AGENT study.This regime has shown superior effectiveness of reducing tumor growth compared to leucovorin and 5-fluorouracil. This better effect is due to a stronger inhibition

Interim Report: 1 January 2020 - 31 March 2020

The Q3 January - March 2020 Interim Report is in the attached PDF file. For more information, please contact: Gustave Geisendorf, CEO at Zutec, gustave.geisendorf@zutec.com, +353 1 201 3565 About Zutec Zutec is a niche provider of cloud-based construction management software. Zutec Holding AB (publ) is listed on Nasdaq First North Growth Market and Mangold Fondkommission AB is the Company’s acting Certified (Tel. + 46 8 5030 1550, CA@mangold.se, www.mangold.se). This information is inside information that Zutec Holding AB (publ) is obliged to make public pursuant to the EU

Bravida aquires ventilation company in Gothenburg

Bravida acquires the company VentFyran i Göteborg AB, and takes a stronger position within ventilation in Gothenburg. The company has 13 employees and a turnover of approximately SEK 33 million.The company VentFyran i Göteborg AB is based on Hisingen, Gothenburg and offers installation and servicing within the ventilation area. The customers are primarily local construction companies, but VentFyran also works directly with industrial companies and real estate companies, among others. “We see the acquisition of VentFyran i Göteborg AB as a step on our journey to become the market leader

Increasing use of gas in Southwest Finland – filling station for heavy-duty vehicles to open in Lieto in the summer

The energy company Gasum is increasing the opportunities to fill up with gas in Southwest Finland with the opening of a new filling station serving heavy-duty vehicles in summer 2020. Located in the Avanti business and industrial area of Lieto, the station will provide liquefied natural gas (LNG) and liquefied biogas (LBG) for the needs of long-haul transport.The gas filling station to open in Lieto will serve long-haul transport by providing low-emission liquefied natural gas (LNG) and biogas (LBG) as fuels. The station will open in the summer of 2020 at Eteläkaari 1 in the Avanti business

Fellow Finance platform facilitated 8,3 million euros of loans in April

FELLOW FINANCE PLC PRESS RELEASE 5.5.2020 AT 8:30 AMIn April, Fellow Finance investors funded business and peer-to-peer loans worth of 8,3M€. Cumulative loan volume grew over 612 million euros and the total number of investors grew to 15 987. Check the real-time peer-to-peer lending statistics on our website: www.fellowfinance.com/for-investor/statistics. The performance of business and consumer loans, intermediated by Fellow Finance, during the COVID-19 pandemic can be followed on the company's website: https://www.fellowfinance.com/for-investor/statistics. The return index takes into

Interim report January-March 2020

Collector AB publishes the interim report for the period January-March 2020.FIRST QUARTER 2020 (COMPARED TO THE FIRST QUARTER 2019) · The loan portfolio increased by 9% to SEK 29,327 million (26,968) · Total income decreased by 3% to SEK 492 million (508) · The C/I ratio amounted to 48.8% (43.2) and the adjusted C/I ratio amounted to 45.7% · The credit loss level amounted to 2.8% (1.3) and the adjusted credit loss level amounted to 2.1% · Operating profit amounted to SEK 44 million (202) and adjusted operating profit amounted to SEK 109 million · Earnings per share

Interim report January – March 2020

January–March 2020 • Rental income increased 13 percent driven by a growing property portfolio. The increase for the comparable portfolio was 2 percent. • Net operating income increased 21 percent, of which 9 percent in the comparable portfolio. • The surplus ratio was strengthened by four percentage points (five percentage points in the comparable portfolio). Low costs for heating and snow clearance are the primary reasons for the increase. During the first quarter in the preceding year, nonrecurring costs occurred, which also contributed to the increase. • Profit from property

Nordic Nanovector Announces US Patent Granted Covering the Use of Betalutin® to Sensitise B-Cell Cancer Cells to CD20 Immunotherapy

Oslo, Norway, 5 May 2020 Nordic Nanovector ASA (OSE:) is pleased to announce the grant of a US patent covering the use of Betalutin® ([177]Lu-satetraxetan-lilotomab) for sensitising CD37-positive B-cell cancer cells before treatment with CD20 immunotherapy (such as rituximab/RTX). The patent strengthens Nordic Nanovector’s overall patent estate around the use of Betalutin® in combination with other drugs that target antigens presented on the surface of tumour cells in patients with B-cell malignancies, such as Non-Hodgkin’s Lymphoma (NHL). The company believes that the combination of

Interim Report January – March 2020

January – March 2020“It has been a unique and challenging quarter for companies around the world with the COVID-19 virus pandemic. We are fortunate to be able to say G5 continued to deliver on its strategy during the first three months of the year, delivering sustainable and profitable growth through our active management and our diversified game portfolio,” said Vlad Suglobov, CEO of G5 Entertainment. “During March we saw a strong increase in overall downloads for our portfolio. We believe this is connected to the introduction of the lockdown policies in numerous countries around the world

First quarter report - 31 March 2020

First quarter 2020 (fourth quarter 2019) · Production from Blocks 3&4, Oman, at 13,032 barrels per day (13,475 barrels per day) · Revenue and other income of MUSD 37.3 (MUSD 36.2) · EBITDA of MUSD 21.9 (MUSD 21.3) · Net result of MUSD 12.1 (MUSD -0.3) · Earnings per share amounted to USD 0.35 (USD -0.01) · Free cash flow MUSD 9.2 (MUSD 4.9) · Net cash MUSD 78.0 (MUSD 75.1) · Blocks 3&4: Production limitations imposed until end of 2020 · Blocks 3&4: Seismic acquisition on the northern part of Blocks 3&4 completed · Block 56: Final government approval of farm-in

Interim report January-March 2020

Railways provide for societyFirst quarter · Consolidated net sales increased by 24.8 per cent to SEK 106.0 million (84.9). · Operating profit (EBIT) increased by SEK 7.0 million to SEK 17.4 million (10.4). · Earnings per share after dilution amounted to SEK 0.54 (0.31). Significant events in the first quarter · In Railcare has not suffered any project cancellations as a consequence of COVID-19. · Machine Sales delivers three generator wagons to the customer. · For Railcare, the season for construction works started early in Sweden.  CEO’s commentsWe achieved

Saga Tankers ASA : Summons to the Annual General Meeting

The Annual General Meeting in Saga Tankers ASA will take place on 26  May 2020 at 10.00hrs (CET) at the premises of the Company at Sjolyst Plass 2, 7th floor in Oslo, Norway. Shareholders may submit their votes electronically in advance. Please see the instructions in the enclosed Notice. The Notice and   the corresponding attachments will be available on the company's webpage www.sagatankers.no under "Investor Relations". For further information, please contact: CEO Espen Lundaas +47 92 43 14 17 This information is subject to the disclosure requirements pursuant to Section 5-12

BERGENBIO RAISES NOK500m (€45.4m) VIA AN OVER SUBSCRIBED PRIVATE PLACEMENT

Bergen, Norway, 5 May 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is pleased to announce that it has raised NOK500m (gross) (€45.4 million) via an over subscribed Private Placement that took place via an accelerated book building process after close of market on 4 May 2020. The Offering was made through the allocation of 13,325,000 shares at a subscription price of NOK 37.50 per share.  BerGenBio intends to use the net proceeds from the Private Placement to take full advantage of

Insta and Kiilto join forces to work on behalf of young people's mental health

The current exceptional circumstances have further increased demand for mental health services for young people. In the spring, Insta and Kiilto, two long-standing family businesses in the Pirkanmaa region in Finland, agreed on charitable collaboration. The companies’ employees voted on the recipient, and as a result of the vote, a donation of EUR 10,000 was made to the Youth Mental Health Association Yeesi, which engages in mental health work providing young people with psychological resources and promoting their wellbeing.Eeva Solja, Brand and Communications Director at Kiilto, is

There are no items matching the current filter
There are no more items matching the current filter
Back to top